These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 26113545

  • 21. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [Abstract] [Full Text] [Related]

  • 22. IgG heavy-chain deposition disease.
    Katz A, Zent R, Bargman JM.
    Mod Pathol; 1994 Oct; 7(8):874-8. PubMed ID: 7838842
    [Abstract] [Full Text] [Related]

  • 23. Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1.
    Moulin B, Deret S, Mariette X, Kourilsky O, Imai H, Dupouet L, Marcellin L, Kolb I, Aucouturier P, Brouet JC, Ronco PM, Mougenot B.
    J Am Soc Nephrol; 1999 Mar; 10(3):519-28. PubMed ID: 10073602
    [Abstract] [Full Text] [Related]

  • 24. Discovery and development of second-generation proteasome inhibitors.
    Kirk CJ.
    Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
    [Abstract] [Full Text] [Related]

  • 25. A case of γ1-heavy chain deposition disease successfully treated with melphalan and prednisolone therapy.
    Oe Y, Nakaya I, Yahata M, Sakuma T, Sato H, Soma J.
    Intern Med; 2010 Jul; 49(14):1411-5. PubMed ID: 20647658
    [Abstract] [Full Text] [Related]

  • 26. Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
    Gu Y, Bouwman P, Greco D, Saarela J, Yadav B, Jonkers J, Kuznetsov SG.
    Cell Death Dis; 2014 Dec 18; 5(12):e1580. PubMed ID: 25522274
    [Abstract] [Full Text] [Related]

  • 27. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B, Li J, Mao X.
    Curr Pharm Des; 2013 Dec 18; 19(18):3190-200. PubMed ID: 23151134
    [Abstract] [Full Text] [Related]

  • 28. Heavy chain deposition disease: the disease spectrum.
    Kambham N, Markowitz GS, Appel GB, Kleiner MJ, Aucouturier P, D'agati VD.
    Am J Kidney Dis; 1999 May 18; 33(5):954-62. PubMed ID: 10213655
    [Abstract] [Full Text] [Related]

  • 29. Long-term renal survival of γ3-heavy chain deposition disease: a case report.
    Katsuno T, Mizuno S, Mabuchi M, Tsuboi N, Komatsuda A, Maruyama S.
    BMC Nephrol; 2017 Jul 17; 18(1):239. PubMed ID: 28716013
    [Abstract] [Full Text] [Related]

  • 30. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 31. Mantle cell lymphoma activation enhances bortezomib sensitivity.
    Brennan SK, Meade B, Wang Q, Merchant AA, Kowalski J, Matsui W.
    Blood; 2010 Nov 18; 116(20):4185-91. PubMed ID: 20570863
    [Abstract] [Full Text] [Related]

  • 32. Immunoglobulin gamma3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia.
    Soma J, Sato K, Sakuma T, Saito H, Sato H, Sato T, Abbas A, Aucouturier P.
    Am J Kidney Dis; 2004 Jan 18; 43(1):E10-6. PubMed ID: 14712467
    [Abstract] [Full Text] [Related]

  • 33. Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib.
    Gelman JS, Sironi J, Berezniuk I, Dasgupta S, Castro LM, Gozzo FC, Ferro ES, Fricker LD.
    PLoS One; 2013 Jan 18; 8(1):e53263. PubMed ID: 23308178
    [Abstract] [Full Text] [Related]

  • 34. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
    Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE.
    Ann Rheum Dis; 2015 Jul 18; 74(7):1474-8. PubMed ID: 25710470
    [Abstract] [Full Text] [Related]

  • 35. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
    Cvek B, Dvorak Z.
    Curr Pharm Des; 2011 Jul 18; 17(15):1483-99. PubMed ID: 21504411
    [Abstract] [Full Text] [Related]

  • 36. Monoclonal immunoglobulin light and heavy chain deposition diseases: molecular models of common renal diseases.
    Ronco P, Plaisier E, Aucouturier P.
    Contrib Nephrol; 2011 Jul 18; 169():221-231. PubMed ID: 21252522
    [Abstract] [Full Text] [Related]

  • 37. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR, Leestemaker Y, Schuurman KG, Ruggeri B, Jones-Bolin S, Williams M, Ovaa H.
    Mol Pharm; 2012 May 07; 9(5):1126-35. PubMed ID: 22432738
    [Abstract] [Full Text] [Related]

  • 38. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
    Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE.
    Nat Med; 2008 Jul 07; 14(7):748-55. PubMed ID: 18542049
    [Abstract] [Full Text] [Related]

  • 39. Proteasome inhibition profoundly affects activated human B cells.
    Mulder A, Heidt S, Vergunst M, Roelen DL, Claas FH.
    Transplantation; 2013 Jun 15; 95(11):1331-7. PubMed ID: 23624544
    [Abstract] [Full Text] [Related]

  • 40. Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons.
    Palanca A, Casafont I, Berciano MT, Lafarga M.
    Cell Mol Life Sci; 2014 May 15; 71(10):1961-75. PubMed ID: 24061536
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.